Urotensin II (UII) is a potent vasoactive peptide that was originally identified in teleost fish. 3
Introduction 1 2
Urotensin II (UII) is a cyclic peptide that was originally isolated from the caudal 3 neurosecretory system, a neuroendocrine system unique to fish (Bern et al. 1985) . 4
Subsequently, UII was identified in amphibia and, more recently, in a number of mammalian 5 species including humans, monkeys, rats and mice (Elshourbagy et al. 2002) . A mammalian 6 UII receptor, designated the UT receptor (Douglas and Ohlstein 2000) , has also been 7 characterised (Ames et al. 1999 ) and mapped to a number of locations, including the brain, 8 kidney, adrenal gland, heart, colon and a variety of blood vessels in humans (Matsushita et 9 al. 2001; Totsune et al. 2001) . Following the discovery of a mammalian UII system, much of 10 the initial attention focussed on the potent vasoactive actions of UII, which appear to be both 11 vessel-and species-specific (Ashton 2006) . However, there is an older literature which 12
suggests that UII may also play a role in body fluid homeostasis (Balment et al. 2005) . UII 13 has been shown to regulate epithelial sodium transport across both absorptive and secretory 14 tissues in fish (Loretz 1985; Marshall and Bern 1979) and it has been implicated in 15 osmoregulation in several teleost species (Bond et al. 2002; Loretz 1985) . Furthermore, 16 recent evidence now suggests that UII may play a role in regulating renal function in 17 mammals. 18 
19
The kidney is a major source of UII in humans (Nothacker et al. 1999) , primates, mice 20 (Elshourbagy et al. 2002) and rats (Song et al. 2006) . UII is found in the urine of humans 21 (Matsushita et al. 2001) and rats (Song et al. 2006) at a concentration far exceeding that of 22 plasma. In humans, the renal clearance of UII is greater than that of creatinine, suggesting 23 that urinary UII is derived primarily from the kidney (Matsushita et al. 2001) . Studies in 24 anaesthetised sheep have revealed an arterio-venous concentration gradient for UII across the 25 renal circulation (Charles et al. 2005) , suggesting that the kidney produces UII in this species 26 too. UT receptors have also been localised to the mammalian kidney: UT mRNA has been 27 identified in human (Matsushita et al. 2001) , monkey, mouse (Elshourbagy et al. 2002) and 28 rat kidneys (Song et al. 2006) . Ligand binding (Disa et al. 2006) and immunohistochemical 29 localisation studies (Song et al. 2006) have identified the medulla, an exclusively tubular 30 component of the kidney, as the principal site of UT receptor expression in the rat kidney. 31
Exposure of LLCPK1 cells, a porcine renal epithelial cell line which expresses UT mRNA, to 32 human UII (hUII) produced a dose-related increase in intracellular calcium (Matsushita et al.
Methods 1 2
The experiments described below were performed in accordance with the UK Animals 3 (Scientific Procedures) Act 1986. 4
5
Renal clearance measurements 6 7 Male Sprague Dawley (SD) rats (250-280g) were prepared for renal clearance studies as 8 described previously (Song et al. 2006) . Rats (n = 7 per group) were anaesthetised (Inactin, 9 thiobutabarbital sodium, 110 mg/kg i.p., Sigma-Aldrich Company Ltd., Poole, Dorset, UK) 10 and the right jugular vein was cannulated for the administration of saline and drugs. A 11 catheter was implanted in the left carotid artery for continuous recording of arterial blood 12 pressure (PowerLab 800/s, ADInstruments, Hastings, East Sussex, UK) and withdrawal of 13 blood samples (0.4 ml). A minimal abdominal incision was made, and a urinary bladder 14 catheter inserted for the collection of urine samples. Body temperature was maintained at 15 PAH (3 mg/h) at 50 µl/min. After a 3 h equilibration period, urine samples were taken every 22 15 min over a 1 h control period; blood samples were taken once per hour for the 23 measurement of electrolyte and clearance marker concentrations. Animals were then divided 24 into three groups which received either vehicle (154 mM NaCl), rat urotensin II (rUII, 25 Peptide Institute, Inc., Osaka, Japan) at 0.6 pmol.min -1 .100g body weight -1 or rUII at 6 26 pmol.min -1 .100g body weight -1 for 1 h. These doses of rUII were chosen to evoke modest, 27 physiologically relevant changes in plasma UII concentrations in the absence of marked 28 vasodepressor effects (Song et al. 2006) . The infusate was then switched back to saline for a 29 further 1 h. Plasma and urine samples were stored at 4°C until assay of inulin and 30 electrolytes was undertaken. Animals were killed humanely at the end of the experiment by 31 anaesthetic overdose. 32
Urine and plasma analysis 1 2 Urine and plasma sodium and potassium concentrations were measured by atomic absorption 3 spectrophotometry (Solaar S Series, Thermo Elemental (Unicam Ltd), Cambridge, UK). 4
Chloride was measured by electrometric titration (Chloride Analyzer 925, Ciba Corning 5 Diagnostics Ltd, Essex, UK). Osmolality was measured using a freezing point depression 6 osmometer (LH Roebling, Berlin, Germany). PAH concentration was measured using a 7 standard colorimetric assay.
3 H-inulin activity was determined using a 1900CA Tri-Carb 8
Liquid Scintillation Analyser (Canberra Industries, Meriden, CT, USA) -counter. 9
10

Measurement of UII in urine 11
12
Urine samples were collected from a separate group of rats (n = 7 per group) for the 13 measurement of UII. Animals were prepared as described above and infused with either 14 vehicle (154 mM NaCl) or rUII at either 0.6 or 6 pmol.min -1 .100g body weight -1 . A 15 min 15 urine sample was collected between 30 and 45 min into the period of vehicle or rUII infusion 16 and stored at -80°C until UII measurement was undertaken. Animals were killed humanely at 17 the end of the experiment by anaesthetic overdose. UII concentrations in urine were 18 measured using a specific radioimmunoassay (RIA) kit (Phoenix Pharmaceuticals, Inc, 19 Burlingame, CA, USA). The detection limit was 2 pg/tube. 20
21
Measurement of Angiotensin II and Tissue Renin Activity 22 23
Blood and urine samples were collected as described above for the measurement of 24 angiotensin II (Ang II). Kidneys were collected from animals at the end of the clearance 25 experiment for the measurement of tissue Ang II and renin activity. Tissue was homogenised 26 on ice in Tris/HCl buffer (pH 7.4, 1 ml buffer per 0.1 g tissue) containing enzymatic 27 inhibitors (1% Triton X-100, 2 mM EDTA, 1 µg/ml leupeptin, 1 µg/ ml aprotinin, 0.1 µg/ml 28 phenylmethylsulphonyl fluoride and 0.1 µg/ml bacitracin) and centrifuged at 1000 g for 20 29 min at 4°C. Prior to the measurement of tissue Ang II, assay buffer containing Captopril (5 30 ng/mg of tissue) was added to each aliquot of homogenised kidney to inhibit Ang II 31 generation in vitro (Sahajpal and Ashton 2005) . Ang II was measured using a commercial 32 radioimmunoassay kit (Euro-Diagnostica AB, Malmo, Sweden). Tissue Ang II concentration1 In order to measure tissue renin activity homogenised kidney samples were diluted in 0.5 M 2 phosphate buffer (pH 6.5) containing 8.8 mM EDTA, 3 mM 8-hydroxyquinoline sulphate and 3 5 mM 2-3-dimercaptropanol to a final concentration of 1:4000 using a 2 step dilution; in the 4 second step 100 µl of renin-free plasma was added. Renal renin activity was measured using 5 a REN-CT2 kit (Cisbio International, Cèze, France) as described previously (Sahajpal and 6 Ashton 2005 Primer Express software (Applied Biosystems, Foster City, CA, USA) and optimised using 21 standard ABI protocols. Quantitative real-time PCR was carried out using an ABI PRISM 22 7500 detector (Applied Biosystems). Relative quantitation values were calculated using the 23 2 -CT method as fold changes in the target gene related to the expression of a control sample 24 (brain), taking into account the amplification efficiency of the primers; data were then 25 normalised to two reference genes ( -actin and GAPDH). All measured variables were in a steady state and did not differ between experimental and 5 control groups prior to the infusion of rUII; mean arterial pressure was unaltered throughout 6 ( Figure 1A ) and the plasma concentration of electrolytes and plasma osmolality remained 7 stable and did not differ between groups (Table 2) . 8 9 Infusion of rat UII at 0.6 pmol.min -1 .100g body weight -1 had no effect on effective renal 10 blood flow (ERBF) ( Figure 1B ). However, glomerular filtration rate (GFR) fell significantly 11 (P < 0.05); GFR dropped to 0.63 ± 0.08 ml.min -1 .100g body weight -1 over the first 15 min 12 collection period after the start of rUII infusion, compared with 1.03 ± 0.05 ml.min -1 . 100g 13 body weight -1 in the vehicle-infused group ( Figure 1C ). The reduction in GFR was sustained 14 until the end of the experiment, 1 h after rUII infusion had ceased. Urine flow rate ( Figure  15 vs rUII 0.6 pmol 9.8 ± 1.1 %). 22
23
Rat UII infusion at the higher rate of 6 pmol.min -1 .100g body weight -1 induced more 24 profound changes in renal haemodynamics including a significant (P < 0.05) reduction in 25 ERBF (vehicle 3.3 ± 0.7 vs rUII 6 pmol 1.4 ± 1.1 ml.min -1 . 100g body weight -1 , Figure 1B ) 26 in the absence of any change in mean arterial pressure ( Figure 1A ). This persisted somewhat 27 after cessation of rUII infusion, only returning to basal levels 45 min after switching back to 28
vehicle. There was also a more pronounced effect on GFR ( Figure 1C ), which was reduced 29 significantly (P < 0.05) and reached a nadir 45 min after the start of rUII infusion (vehicle 30 1.03 ± 0.06 vs rUII 6 pmol 0.31 ± 0.05 ml.min -1 . 100g body weight -1 ). GFR had not returned 31 to control levels by the end of the experiment, 1 h after rUII infusion had ceased ( Figure 1C) . 32
This pattern of greatly reduced filtered load was reflected in the lowered urine flow ( Figure  1 2A) and electrolyte excretion rates ( Figure 2B ). There were significant (P < 0.05) reductions 2 in urine flow rate (vehicle 25.9 ± 4.1 vs rUII 6 pmol 5.8 ± 1.8 µl.min -1 . 100g body weight -1 ) 3 and the urinary excretion of Na + (vehicle 2.6 ± 0.4 vs rUII 6 pmol 0.6 ± 0.2 µmol.min -1 . 100g 4 body weight -1 ), K + (vehicle 1.6 ± 0.1 vs rUII 6 pmol 0.3 ± 0.1 µmol.min -1 . 100g body 5 weight -1 ) and Cl -(vehicle 4.7 ± 0.3 vs rUII 6 pmol 0.9 ± 0.3 µmol.min -1 . 100g body weight -6 1 ), which reached a nadir 30 min after the infusion of rUII commenced. These reductions in 7 electrolyte excretion were accompanied by a trend towards higher fractional excretion rates 8 but this did not reach statistical significance ( Figure 2C ). 9 10 Urotensin II and angiotensin II concentrations and tissue renin activity 11
12
Infusion of rUII raised the urinary UII concentration from 2.8 ± 0.1 x 10 -8 M for the vehicle-13 infused group to 3.7 ± 0.2 x 10 -8 M and 6.4 ± 0.6 x 10 -8 M for rUII at 0.6 and 6 pmol.min -14 1 .100g body weight -1 , respectively (P < 0.05). Constant infusion of UII tended to decrease 15 both plasma and renal tissue Ang II concentrations whereas renal tissure renin activity tended 16 to increase, but these differences did not reach statistical significance. However, there was a 17 significant (P < 0.05) dose-related reduction in the concentration of Ang II in the urine of rats 18 receiving rUII infusion (Table 3) . 19
20
Renal UII and UT receptor expression 21 22
The relative mRNA expression levels of UII and UT receptor were determined in kidney 23 cortex and medulla by real-time qPCR. UII (P < 0.01) and UT (P < 0.05) mRNA expression 24 levels were significantly greater in the medulla than in the cortex ( Figure 3A) . Western blot 25 analysis revealed a similar pattern of expression for the UT receptor. A band was detected at 26 60 kDa, corresponding with the glycosylated form of the UT receptor (Boucard et al. 2003) , 27 in both cortex and medulla. Densitometric analysis of the UT band, normalised to the protein 28 loading control GAPDH, showed that UT expression was significantly greater (P < 0.05) in
This study provides functional evidence that UII influences tubular sodium and potassium 3 transport, in addition to effects on the renal vasculature. Specifically, rUII infusion at the 4 lower of the two doses employed (0.6 pmol.min -1 .100g body weight -1 ) was associated with an 5 increase in the fractional excretion of sodium and potassium, likely reflecting an inhibition of 6 tubular reabsorption. This contrasts with the marked antinatriuresis and antikaliuresis 7 produced with the higher dose rUII infusion, which were driven by the profound reduction in 8 GFR and thus filtered load of electrolytes. 9
10
The pronounced reductions in urine flow and electrolyte excretion rates evoked by rUII 11 infusion at the higher dose of 6 pmol.min -1 .100g body weight -1 mirror the changes seen in 12 GFR and are consistent with our observations following bolus administration of rUII (Song et 13 al. 2006) . Thus any coincidental tubular action of rUII was masked by the predominant 14 decrease in filtered load of water and ions. Indeed, when the lower dose of rUII, which had 15 much less impact upon GFR, was infused a different pattern of response emerged. In these 16 animals, despite the modest fall in filtered load, urine flow rate and urinary sodium excretion 17 did not differ from vehicle-treated rats. This was a result of a significant increase in the 18 fraction of filtered sodium that was excreted, indicating reduced tubular reabsorption. A 19 similar increase in the fractional excretion of potassium was also observed. These 20 observations differ somewhat from our previous report of the effects of infusing a UT 21 receptor antagonist, urantide, on renal function (Song et al. 2006) , and may be explained by 22 the different backgrounds against which measurement were made. In our earlier study, 23 infusion of urantide was associated with a pronounced diuresis and natriuresis; the fractional 24 excretion of potassium was reduced significantly and that of sodium tended to increase. In 25 the current study, rUII infusion at 0.6 pmol.min -1 .100g body weight -1 had no effect on urine 26 flow and electrolyte excretion rates, but was associated with significant increases in the 27 fractional excretion of sodium and potassium. The apparent discrepancy in fractional sodium 28 excretion between the two studies probably reflects the very different background urine flow 29 rates, which were driven in part by changes in GFR. 30
31
Other groups have reported a variety of renal responses to UII infusion in the rat. Zhang et 32 al. (2003) observed an increase in fractional sodium excretion following intra-renal infusionaccompanied by no change in GFR. In contrast, Ovcharenko et al. (2006) observed no 1 change in sodium excretion or fractional excretion of sodium in response to bolus injections 2 of hUII in Wistar rats. In the latter study hUII produced a modest reduction in renal blood 3 flow, no change in GFR, yet mean arterial pressure fell by 30 mmHg. Some of the 4 differences between earlier studies may be due to the varying doses of UII employed. We 5 measured circulating plasma UII in the SD rat in the low pmol range (Song et al. 2006) and 6 therefore have used bolus and continuous infusions of UII in the low pmol / 100g body 7 weight range, to effect manipulations within a physiologically relevant range. In the current 8 study this resulted in a 2-fold increase in urinary UII concentration at the highest dose 9 employed; a similar increase in urinary UII concentration has been reported in patients with 10 renal disease (Totsune et al. 2004) . Previous clearance studies in rats have injected bolus 11 doses systemically at 1-100 nmol/kg (Ovcharenko et al. 2006) or infused at 2.5-20 ng.kg -12
1 .min -1 directly into the renal artery (Zhang et al. 2003) , which potentially exposed the kidney 13 to supraphysiological doses of the hormone. The heterologous nature of the peptides used in 14 these studies is unlikely to have had a significant impact on the outcome, as the UT receptor 15 is unable to distinguish between UII from a number of species, including human and rat 16 (Labarrere et al. 2003) . 17 18 The increase in fractional excretion of sodium and potassium evoked by rUII in the current 19 study, and by hUII in Zhang's experiments (Zhang et al. 2003) , suggest that UII acts to 20 inhibit renal tubular epithelial Na + and K + transport. A similar inhibitory action on Na + and 21
Cl
-transport has been observed in epithelial cells of the skin and opercular membrane of fish 22 (Loretz et al. 1981; Marshall and Bern 1981) . The precise tubular site at which UII exerts 23 this inhibitory action in the rat kidney is not yet known, nor is it clear whether UII has a 24 direct effect on epithelial transport or works through an intermediary. However, radio-ligand 25 binding studies (Disa et al. 2006) coupled with the UT mRNA and protein expression data 26 reported herein place the majority of UT receptors in the renal medulla. This is consistent 27 with immuno-localisation of the UT receptor, which has identified the thin ascending limbs 28 of the loop of Henlé and the inner medullary collecting duct as likely sites (Song et al. 2006) . 29
Unfortunately, these parts of the nephron are not readily accessible to micropuncture, so 30 direct measurements of sodium flux cannot be made in vivo. 31 a 60 kDa glycosylated form of the receptor was identified, but no signal was seen at 43 kDa. 3
Confirmation of the nature of the 60 kDa band was provided following deglycosylation 4 which resulted in a shift from 60 kDa to 42 kDa (Boucard et al. 2003) . Interestingly, 5
Boussete et al. (2006) also observed bands at 150 kDa and 200 kDa which they attributed to 6 the formation of hetero-and homo-oligomeric complexes. Although present in normal heart, 7 these bands were much more prominent in congestive heart failure: we did not observe any 8 bands other than the 60 kDa in the kidney. 9 10 Expression analysis showed that more UII mRNA was found in the medulla compared with 11 the cortex. This is consistent with immuno-localisation studies, which identified UII-like 12 immunoreactivity in the proximal tubule and both outer and inner medullary collecting ducts, 13 the latter being in close proximity to UT expression (Song et al. 2006) . This suggests that the 14 kidney may be the principal site of origin of the immunoreactive-UII measured in rat urine 15 and also lends support to the notion that UII acts to inhibit electrolyte transport by the renal 16 tubule, independent of any actions on renal haemodynamics. 17
18
Systemic administration of rUII produced dose-related reductions in both GFR and RBF, 19 however, the effect on the former was greater in magnitude. These observations are 20 consistent with Gardiner and colleagues' report of a modest reduction in renal blood flow in 21 conscious SD rats following either bolus injection (Gardiner et al. 2001) or 6 h infusion 22 (Gardiner et al. 2006) of hUII. The effects of hUII on renal blood flow were blocked by 23 indomethacin and attenuated by L-NAME (Gardiner et al. 2006) implying that 24 cyclooxygenase products and nitric oxide were involved in the response to hUII. A similar 25 nitric oxide-dependent vasodilatation was observed when small renal arteries (250-300 µm 26 internal diameter) were exposed to hUII in vitro (Zhang et al. 2003) . However, the actions of 27 UII on smaller glomerular arterioles remain to be determined. On the basis of our 28 observations, namely modest reductions in RBF accompanied by a marked reduction in GFR, 29 it seems likely that UII was acting predominantly at the efferent arteriole. Afferent arteriole 30 constriction tends to reduce RBF and GFR to a similar degree, whereas efferent arteriole 31 dilatation has a greater effect on GFR (Dworkin and Brenner 1996) , which is consistent with 32 the observed actions of rUII in our hands. 33
As UII has been shown to act synergistically with Ang II to induce contraction of the rat 1 thoracic aorta (Lamarre and Tallarida 2008; Wang et al. 2007 ), we measured plasma, urine 2 and renal tissue Ang II concentrations and renal tissue renin activity in rats receiving a 3 continuous infusion of rUII to determine whether the actions of rUII were influenced by Ang 4 II. Neither plasma nor tissue Ang II concentrations nor renal tissue renin activity differed 5 significantly at either rUII infusion rate. This appears to be at odds with the reduction in 6 GFR observed upon rUII infusion, as one might predict a compensatory increase in renin 7 secretion and thus intrarenal Ang II generation following such a profound drop in GFR (Ito 8 and Abe 1997). If, as we propose, UII acts at the efferent arteriole to cause dilatation and a 9 reduction in post-glomerular resistance, autoregulatory processes should act to increase 10 glomerular capillary hydrostatic pressure to restore GFR. This did not occur over the 1 h 11 rUII infusion period; indeed, GFR remained lower than that in vehicle-infused rats once the 12 infusate had been switched back to saline. Similar sustained responses beyond the period of 13 rUII infusion were also observed for a number of renal variables in this study and in our 14 earlier report (Song et al. 2006) . This is consistent with the very slow UT receptor 15 dissociation rate (K d ~ 0.1 nM (Ames et al. 1999) ) which has lead to the suggestion that UII 16 binding is 'pseudo-irreversible ' (Douglas et al. 2004) . 17 18 In contrast to the lack of change in plasma and tissue Ang II concentrations, UII infusion was 19 associated with a dose-related reduction in urinary Ang II concentration. As circulating Ang 20 II is filtered by the glomerulus, the dose-related reduction in urinary Ang II concentration 21 may simply reflect the rUII-induced decrease in GFR and hence the amount of filtered Ang II 22 entering the tubular fluid. Ang II is also generated within the tubular fluid itself. Little or no 23 angiotensinogen passes through the glomerular filtration barrier, however, proximal tubules 24 have been reported to secrete angiotensinogen into the tubular fluid (Rohrwasser et al. 1999) . 25
In conjunction with renin, which is both filtered and secreted by connecting tubule cells 26 (Rohrwasser et al. 1999) , and angiotensin converting enzyme, which is expressed abundantly 27 throughout the tubule and on renal endothelial cells (Casarini et al. 1997) , secretion of 28 angiotensinogen may lead to Ang II formation within the tubular fluid. Thus it is possible 29 that rUII may have interacted with the intraluminal generation of Ang II. However in view of 30 the lack of change in renal tissue Ang II content, is seems likely that a reduction in filtered 31
Ang II was primarily responsible for the observed reduction in urinary Ang II concentration. 32
In summary, this study provides evidence that rUII has not only haemodynamic but also 1 tubular actions on the rat kidney, when infused at a non-depressor, physiologically relevant 2 dose. The haemodynamic effects predominate at higher doses, causing a profound reduction 3 in GFR which is accompanied by an antidiuresis and antinatriuresis. When a lower infusion 4 rate of rUII was employed, a tubular action to reduce electrolyte reabsorption became 5 apparent through an increase in fractional excretion of sodium and potassium. Whether this 6 was a direct effect on tubular transport or was mediated via a secondary mechanism is not 7 clear from the available data. However, immuno-localisation showed that the UT receptor is 8 expressed in the thin ascending limb of the loop of Henlé and the inner medullary collecting 9 duct (Song et al. 2006) , consistent with the greater UT mRNA and protein expression 10 observed in the medulla compared with the cortex, which suggests that UII may indeed have 11 a direct action on tubular electrolyte transport. The role of endogenous UII in the day-to-day 12 regulation of renal function remains to be determined, but this study adds further weight to 13 the suggestion that UII is one of a number of intrarenal peptides that contributes to the control 14 of the kidney. In view of the reported increases in plasma or urinary UII concentrations in 15 hypertension (Cheung et al. 2004) , congestive heart failure (Russell et al. 2003) Statistical analysis was by t-test. * P < 0.05; ** P < 0.01 cortex vs medulla. 21 Table 2 . Plasma electrolytes and osmolality measured in rats receiving a constant i.v.
infusion of either vehicle (n = 7) or rUII at 0.6 (n = 7) or 6.0 (n = 7) pmol.min -1 .100g body weight -1 for 1 hour.
Vehicle Rat urotensin II Table 3 . Plasma, urine and renal tissue angiotensin II (Ang II) concentrations and renal tissue renin activity in rats receiving a constant i.v. infusion of either vehicle (n = 7) or rUII at 0.6 (n = 7) or 6.0 (n = 7) pmol.min 
